Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 77 | 0.79 |
| pathways Reactome | 1 pathway; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 12324
Sealed predictions
- ACOT7 in dopamine neurons, braak-0.19 (p 0.630) → -0.28 (p 0.470)receipt 12331
Swarm cases
receipt 12331: ACOT7 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.393, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.393, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.135, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.393, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.77 (p 1.8e-4, n 18) vs -0.21 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACOT7 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ACOT7 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 1.8e-4)
Receipts
loading the receipts